Finance

Beta
Lists
INCY:NASDAQ
Incyte Corp
$106.43
+1.94%
(+2.03) 1D
Jun 24, 9:32:44 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INCY...
Open
$105.53
High
$106.43
Low
$104.49
Mkt. cap
21.26B
Avg. vol.
1.84M
Volume
189.00
P/E ratio
15.05
52-wk high
$112.29
52-wk low
$66.83
EPS
$7.07
Beta
0.79
Shares outstanding
199.78M
No. of employees
3K
Open
$105.53
High
$106.43
Low
$104.49
Mkt. cap
21.26B
Avg. vol.
1.84M
Volume
189.00
P/E ratio
15.05
52-wk high
$112.29
52-wk low
$66.83
EPS
$7.07
Beta
0.79
Shares outstanding
199.78M
No. of employees
3K
News stories
From sources across the web
Profile
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity. Wikipedia
About Incyte Corp
CEOHervé Hoppenot
Employees2.84K
Founded2002
HeadquartersWilmington, Delaware, United States
SectorBiotechnology
Websiteincyte.com
Analyst Ratings
Based on 20 analysts giving stock ratings to INCY in the past 3 months
Buy
Buy
9
Hold
11
Sell
0
12 month forecast
Based on 20 Wall Street analysts offering 12 month price targets for INCY in the last 3 months.
Highest
Current $106.43
$140.00 (+31.54%)
Average
$112.39 (+5.60%)
Lowest
$94.00 (-11.68%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$140.00
+31.5%
06/24/2026
Etzer Darout
Barclays
Buy
Maintained
$117.00
+9.9%
06/23/2026
Marc Frahm
TD Cowen
Buy
Maintained
$124.00
+16.5%
06/22/2026
Srikripa Devarakonda
Truist Financial
Hold
Reiterated
$105.00
-1.3%
06/23/2026
Evan Seigerman
BMO Capital
Hold
Upgraded
$94.00
-11.7%
06/22/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$121.00
+13.7%
06/18/2026
Derek Archila
Wells Fargo
Hold
Maintained
$101.00
-5.1%
06/17/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$123.00
+15.6%
06/15/2026
Salveen Richter
Goldman Sachs
Hold
Maintained
$100.00
-6%
06/15/2026
Judah Frommer
Morgan Stanley
Hold
Maintained
$103.00
-3.2%
06/15/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
$124.00
+16.5%
06/15/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$136.00
+27.8%
06/15/2026
Matt Phipps
William Blair
Hold
Maintained
-
-
06/15/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
$110.00
+3.4%
06/09/2026
Ashwani Verma
UBS
Hold
Maintained
$103.00
-3.2%
06/08/2026
Jay Olson
Oppenheimer
Hold
Maintained
$107.00
+0.5%
06/08/2026
Unknown Analyst
Bernstein
Hold
Maintained
-
-
06/01/2026
Unknown Analyst
J.P. Morgan
Hold
Maintained
$105.00
-1.3%
05/20/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$130.00
+22.1%
05/04/2026
Unknown Analyst
Argus Research
Buy
Maintained
$115.00
+8.1%
04/30/2026
Brian Abrahams
RBC Capital
Hold
Maintained
$95.00
-10.7%
04/28/2026
Faisal Khurshid
Jefferies
Hold
Downgraded
$94.00
-11.7%
03/15/2026
Unknown Analyst
Evercore ISI
Hold
Maintained
$110.00
+3.4%
03/05/2026
Last report
Apr 28, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$1.81 / $1.34
+35.12%beat
Revenue / Est. (USD)
1.27B / 1.21B
+5.07%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.22B
1.37B
1.51B
1.27B
Cost of goods sold
573.68M
605.58M
732.55M
620.43M
Cost of revenue
573.68M
605.58M
732.55M
620.43M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
330.26M
328.29M
388.96M
327.06M
Operating expense
330.26M
328.29M
388.96M
327.06M
Total operating expenses
903.94M
933.87M
1.12B
947.49M
Operating income
311.59M
432.11M
385.32M
325.19M
Other non operating income
6.54M
3.25M
4.22M
1.75M
EBT including unusual items
558.01M
482.31M
389.94M
343.60M
EBT excluding unusual items
342.67M
461.55M
419.71M
360.06M
Income tax expense
153.01M
58.14M
90.66M
40.27M
Effective tax rate
27.42%
12.05%
23.25%
11.72%
Other operating expenses
-
-
-
-
Net income
405.00M
424.17M
299.28M
303.33M
Net profit margin
33.32%
31.05%
19.86%
23.83%
Earnings per share
1.57
2.26
1.80
1.81
Interest and investment income
25.14M
26.78M
30.75M
33.69M
Interest expense
-594.00K
-592.00K
-582.00K
-569.00K
Net interest expenses
24.54M
26.19M
30.17M
33.12M
Depreciation and amortization charges
-
-
-
-
EBITDA
334.51M
456.13M
409.30M
348.99M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer